These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35241398)

  • 21. Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
    Ma L; Waldmann E; Ooi EMM; Chan DC; Barrett HPR; Watts GF; Parhofer KG
    Eur J Clin Invest; 2019 Feb; 49(2):e13053. PubMed ID: 30447089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
    Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
    Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apolipoprotein A-I Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles.
    Bekaert ED; Alaupovic P; Knight-Gibson CS; Franceschini G; Sirtori CR
    J Lipid Res; 1993 Jan; 34(1):111-23. PubMed ID: 8445335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
    Pischon T; Girman CJ; Sacks FM; Rifai N; Stampfer MJ; Rimm EB
    Circulation; 2005 Nov; 112(22):3375-83. PubMed ID: 16316964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apolipoprotein B: the Rosetta Stone of lipidology.
    Glavinovic T; Sniderman AD
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):90-96. PubMed ID: 33229928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
    Sniderman A; McQueen M; Contois J; Williams K; Furberg CD
    J Clin Lipidol; 2010; 4(3):152-5. PubMed ID: 21122647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making.
    Cole J; Otvos JD; Remaley AT
    Clin Chem; 2023 Jan; 69(1):41-47. PubMed ID: 36366949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner.
    Assini JM; Clark JR; Youssef A; Xing C; Doerfler AM; Park SH; Saxena L; Yaseen AB; Børen J; Gros R; Bao G; Lagor WR; Boffa MB; Koschinsky ML
    Atherosclerosis; 2023 Nov; 384():117150. PubMed ID: 37290980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipoprotein profiles, not anthropometric measures, correlate with serum lipoprotein(a) values in children: the Taipei children heart study.
    Chu NF; Makowski L; Chang JB; Wang DJ; Liou SH; Shieh SM
    Eur J Epidemiol; 2000 Jan; 16(1):5-12. PubMed ID: 10780336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease.
    Rasouli M; Kiasari AM; Mokhberi V
    Clin Chem Lab Med; 2006; 44(8):1015-21. PubMed ID: 16879071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
    Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
    Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
    Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
    Kimak E; Solski J; Janicka L; Ksaziek A; Janicki K
    Clin Chem Lab Med; 2000 May; 38(5):421-5. PubMed ID: 10952225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
    Albers JJ; Slee A; O'Brien KD; Robinson JG; Kashyap ML; Kwiterovich PO; Xu P; Marcovina SM
    J Am Coll Cardiol; 2013 Oct; 62(17):1575-9. PubMed ID: 23973688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
    Cubrilo-Turek M; Sertić J; Duraković Z
    Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors.
    Dansinger ML; Williams PT; Superko HR; Schaefer EJ
    Lipids Health Dis; 2019 Jul; 18(1):154. PubMed ID: 31311555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
    Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.